J Psychopharmacol
December 17, 2022
Miriam Marguilho, Inês Figueiredo, Pedro Castro-Rodrigues
57 citations
Ketamine, an NMDA antagonist used for depression, produces rapid but transient antidepressant effects primarily through acute modulation of reward circuits and a sub-acute increase in neuroplasticity. Its dissociative and psychedelic properties arise from dose- and context-dependent disruption of large-scale functional networks: disruption of the salience network accounts for dissociation, while disruption of the default-mode network accounts for the psychedelic state. In psychedelic-assisted psychotherapy, relaxing high-level beliefs with support may allow revision of pathological self-representation models, with neuroplasticity playing a permissive role. This multi-level account suggests leveraging ketamine's psychedelic properties to enhance long-term benefits.
Cureus
January 29, 2025
Sorcha O'Connor, Kate Godfrey, Sara Reed et al.
2 citations
The study aims to uncover the neural mechanisms by which psilocybin-assisted therapy affects obsessive-compulsive disorder (OCD) and whether those brain changes align with improvements in cognitive symptoms. A secondary goal is to test whether a low, tolerable dose is both practical and effective as a clinical treatment. The results will provide essential data for designing a future randomized controlled trial.
General hospital psychiatry
January 1, 2026
Rebeca Cohen, João Bastos, Catarina Cunha et al.
1 citation
A case series of 12 patients with treatment-resistant depression treated with a novel protocol combining ketamine injections (0.5-1.5 mg/kg intramuscularly, 5-8 sessions) and brief psychodynamic psychotherapy found that 67% responded and 58% achieved remission. Half of the patients maintained remission at 3-month and 1-year follow-ups. Ego dissolution during the third ketamine session correlated with symptom improvement and psychological insight. The results suggest that combining ketamine with psychotherapy may enhance and prolong antidepressant effects beyond ketamine alone.
Cureus
January 1, 2025
Sorcha O'Connor, Kate Godfrey, Sara Reed et al.
correction
A protocol describes a planned study testing whether a low-moderate dose of psilocybin (10 mg), combined with non-interventional therapy, can improve cognitive flexibility and neuroplasticity in people with obsessive-compulsive disorder (OCD). Twenty blinded participants will receive an active placebo (1 mg psilocybin) in a first session and 10 mg in a second session four weeks later. Cognitive flexibility will be measured with the intradimensional-extradimensional shift task two days after each session, and neuroplasticity will be assessed via electroencephalography immediately after each session. Secondary outcomes include OCD symptom severity and patient-reported measures. The results are expected to clarify neural mechanisms and guide a future randomized controlled trial.